Home
/ Anvyl
/ Competitors

Anvyl Competitors and Similar CompaniesClear all

Anvyl's competitors and similar companies include Genentech, Ipsen, CSL Behring and UCB.

	Anvyl Anvyl is a company developing therapies for the treatment of cognitive-deficit disorders and other disorders of the central nervous system (CNS).	Genentech Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines.	Ipsen Ipsen is a biopharmaceutical company.	CSL Behring CSL Behring is a provider of life-saving medicines.	UCB UCB is a company that provides biopharmaceutical research and development solutions for neurological and immunological conditions.
Founding Date	Founding Date N/A	Founding Date 1976	Founding Date 1929	Founding Date 1904	Founding Date 1928
Type	Type Private	Type Subsidiary	Type Public	Type Subsidiary	Type Public
Tags	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma
Locations	Locations HQ	Locations South San Francisco, US HQ Hillsboro, US Oceanside, US Portland, US South San Francisco, US South San Francisco, US South San Francisco, US see more	Locations Boulogne-Billancourt, FR HQ Algiers, DZ South Yarra, AU Wien, AT Merelbeke, BE São Paulo, BR Mississauga, CA see more	Locations King of Prussia, US HQ Broadmeadows, AU Parkville, AU Parkville, AU Wien, AT Mechelen, BE see more	Locations Brussels, BE HQ Melbourne, AU Vienna, AT Braine L'alleud, BE Braine L'alleud, BE Leuven, BE São Paulo, BR see more
Employees	Employees 3	Employees 18,077	Employees 5,358	Employees 7,5692% decrease	Employees 9,052
Valuation ($)	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) 10.2 b	Valuation ($) N/A	Valuation ($) 34.3 b
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) €3.7b (FY, 2025)	Revenue (est.) $7.9b (FY, 2020)	Revenue (est.) €7.4b (FY, 2025)
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods €659.1m (FY, 2025)	Cost of goods N/A	Cost of goods €1.4b (FY, 2025)
Gross profit	Gross profit N/A	Gross profit N/A	Gross profit €3.3b (FY, 2025)	Gross profit $4.5b (FY, 2020)	Gross profit €7.2b (FY, 2025)
Net income	Net income N/A	Net income N/A	Net income €445.1m (FY, 2025)	Net income N/A	Net income €1.6b (FY, 2025)
Operating ⚠
Countries	Countries N/A	Countries N/A	Countries N/A	Countries 100 (Dec, 2020)	Countries 35 (FY, 2019)